4D MOLECULAR THERAPEUTICS IN (FDMT) Forecast, Price Target & Analyst Ratings
NASDAQ:FDMT • US35104E1001
8.64 USD
-0.29 (-3.25%)
At close: Mar 5, 2026
8.64 USD
0 (0%)
After Hours: 3/5/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for 4D MOLECULAR THERAPEUTICS IN (FDMT).
Forecast Snapshot
Consensus Price Target
$32.90
+ 280.73% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ4 / 2025
EPS Estimate-$0.78
Revenue Estimate9.364M
ChartMill Buy Consensus
82.35%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$32.90
Upside
+ 280.73%
From current price of $8.64 to mean target of $32.90, Based on 17 analyst forecasts
Low
$17.17
Median
$33.15
High
$47.25
Price Target Revisions
1 Month
-2.60%
3 Months
-2.60%
Price Target Summary
17 analysts have analysed FDMT and the average price target is 32.9 USD. This implies a price increase of 280.73% is expected in the next year compared to the current price of 8.64.
The average price target has been revised downward by 2.6% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.35%
FDMT was analyzed by 17 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about FDMT.
In the previous month the buy percentage consensus was at a similar level.
FDMT was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-28 | Barclays | Initiate | Overweight |
| 2025-12-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-11 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-21 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-08-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-12 | Roth Capital | Maintains | Buy -> Buy |
| 2025-08-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-09 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-03-10 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-13 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-01-13 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | B of A Securities | Maintains | Buy -> Buy |
| 2024-11-21 | Morgan Stanley | Initiate | Underweight |
| 2024-11-14 | Chardan Capital | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ4 / 2025
EPS Estimate-$0.78
Revenue Estimate9.364M
Revenue Q2Q936,300.00%
EPS Q2Q13.58%
Number of Analysts12
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
FDMT is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.78 USD and the consensus revenue estimate is 9.36M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.13M -82.65% | 20.723M 562.08% | 37K -99.82% | 7.891M 21,227.03% | 20.664M 161.87% | 21.755M 5.28% | 35.241M 61.99% | 128.2M 263.78% | 289.45M 125.78% | 538.89M 86.18% | 848.9M 57.53% | 1.482B 74.58% | |
| EBITDA YoY % growth | -107.63M -54.18% | -108.663M -0.96% | -183.188M -68.58% | -213.305M -16.44% | -244.946M -14.83% | -275.877M -12.63% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -110.03M -54.25% | -112.867M -2.58% | -187.841M -66.43% | -215.646M -14.80% | -247.639M -14.84% | -278.866M -12.61% | -371.2M -33.11% | -389.536M -4.94% | -291.014M 25.29% | -119.296M 59.01% | 115.34M 196.68% | 624.17M 441.16% | |
| Operating Margin | -3,515.34% | -544.65% | -507,678.38% | -2,732.81% | -1,198.41% | -1,281.85% | -1,053.32% | -303.85% | -100.54% | -22.14% | 13.59% | 42.12% | |
| EPS YoY % growth | -3.32 -29.69% | -2.64 20.48% | -2.98 -12.88% | -3.75 -25.86% | -3.55 5.39% | -3.52 0.90% | -3.98 -13.13% | -4.15 -4.27% | -2.86 31.07% | -0.68 76.22% | 1.89 377.49% | 7.16 279.19% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.78 13.58% | -0.95 -10.70% | -0.89 9.10% | -0.92 8.77% | -0.85 -9.51% |
| Revenue Q2Q % growth | 9.364M 936,300.00% | 8.16M 58,185.71% | 8.16M 54,300.00% | 8.16M 8,966.67% | 8.16M -12.86% |
| EBITDA Q2Q % growth | -61.81M -20.10% | -57.369M -9.13% | -60.327M -5.39% | -64.808M -12.30% | N/A |
| EBIT Q2Q % growth | -58.609M -4.44% | -62.209M -16.02% | -64.068M -7.76% | -66.695M -9.01% | -67.762M -15.62% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-5.67%
EPS Next 5 Year
-6.84%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
140.60%
Revenue Next 5 Year
141.46%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-14.19%
EBIT Next 5 Year
N/A
4D MOLECULAR THERAPEUTICS IN / FDMT Forecast FAQ
Can you provide the average price target for 4D MOLECULAR THERAPEUTICS IN stock?
17 analysts have analysed FDMT and the average price target is 32.9 USD. This implies a price increase of 280.73% is expected in the next year compared to the current price of 8.64.
When does 4D MOLECULAR THERAPEUTICS IN (FDMT) report earnings?
4D MOLECULAR THERAPEUTICS IN (FDMT) will report earnings on 2026-05-06.
What are the consensus estimates for 4D MOLECULAR THERAPEUTICS IN (FDMT) next earnings?
The consensus EPS estimate for the next earnings of 4D MOLECULAR THERAPEUTICS IN (FDMT) is -0.78 USD and the consensus revenue estimate is 9.36M USD.
Can you provide the expected long term growth rate for 4D MOLECULAR THERAPEUTICS IN stock?
The expected long term growth rate for 4D MOLECULAR THERAPEUTICS IN (FDMT) is 140.6%.